{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:59:40Z","timestamp":1793948380713,"version":"4.8.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,1,11]],"date-time":"2023-01-11T00:00:00Z","timestamp":1673395200000},"content-version":"vor","delay-in-days":1106,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["MA5799\/2-1"],"award-info":[{"award-number":["MA5799\/2-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["li.uscap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Laboratory Investigation"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1038\/s41374-019-0298-6","type":"journal-article","created":{"date-parts":[[2019,8,13]],"date-time":"2019-08-13T08:03:18Z","timestamp":1565683398000},"page":"27-37","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":42,"title":["NSG mice as hosts for oncological precision medicine"],"prefix":"10.1016","volume":"100","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8389-8439","authenticated-orcid":false,"given":"Claudia","family":"Maletzki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephanie","family":"Bock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philipp","family":"Fruh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karolis","family":"Macius","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anika","family":"Witt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Friedrich","family":"Prall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Linnebacher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1038\/s41374-019-0298-6_bib1","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13045-017-0470-7","article-title":"Current status and perspectives of patient-derived xenograft models in cancer research","volume":"10","author":"Lai","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1038\/s41374-019-0298-6_bib2","doi-asserted-by":"crossref","first-page":"e62","DOI":"10.1158\/0008-5472.CAN-17-0582","article-title":"PDX-MI: minimal information for patient-derived tumor xenograft models","volume":"77","author":"Meehan","year":"2017","journal-title":"Cancer Res"},{"key":"10.1038\/s41374-019-0298-6_bib3","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/nrc.2016.140","article-title":"Interrogating open issues in cancer precision medicine with patient-derived xenografts","volume":"17","author":"Byrne","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/s41374-019-0298-6_bib4","first-page":"3","article-title":"Patient-derived xenograft mouse models: a high fidelity tool for individualized medicine","volume":"17","author":"Xu","year":"2019","journal-title":"Oncol Lett"},{"key":"10.1038\/s41374-019-0298-6_bib5","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/978-1-4939-6527-4_16","article-title":"Generation of xenotransplants from human cancer biopsies to assess anti-cancer activities of HDACi","volume":"1510","author":"Mullins","year":"2017","journal-title":"Methods Mol Biol"},{"key":"10.1038\/s41374-019-0298-6_bib6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4143\/crt.2017.307","article-title":"The generation and application of patient derived xenograft (PDX) model for cancer research","volume":"50","author":"Jung","year":"2017","journal-title":"Cancer Res Treat"},{"issue":"1","key":"10.1038\/s41374-019-0298-6_bib7","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1111\/j.1749-6632.2011.06310.x","article-title":"Humanized mice as a preclinical tool for infectious disease and biomedical research","volume":"1245","author":"Shultz","year":"2011","journal-title":"Annals of the New York Academy of Sciences"},{"key":"10.1038\/s41374-019-0298-6_bib8","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.canlet.2013.10.015","article-title":"Humanized NOD-SCID IL2rg \u2013\/\u2013 mice as a preclinical model for cancer research and its potential use for individualized cancer therapies","volume":"344","author":"Zhou","year":"2014","journal-title":"Cancer Lett."},{"key":"10.1038\/s41374-019-0298-6_bib9","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrc.2016.91","article-title":"Mouse models in oncoimmunology","volume":"16","author":"Zitvogel","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1038\/s41374-019-0298-6_bib10","first-page":"1","article-title":"A review of the evolution of systemic chemotherapy in the management of colorectal cancer","volume":"14","author":"Gustavsson","year":"2015","journal-title":"Clin Colorectal Cancer."},{"key":"10.1038\/s41374-019-0298-6_bib11","doi-asserted-by":"crossref","first-page":"6896024","DOI":"10.1155\/2016\/6896024","article-title":"Predictive biomarkers in colorectal cancer: from the single therapeutic target to a plethora of options","volume":"2016","author":"Rodrigues","year":"2016","journal-title":"Biomed Res Int."},{"key":"10.1038\/s41374-019-0298-6_bib12","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1007\/s10689-013-9633-z","article-title":"Chemotherapy of MMR-deficient colorectal cancer","volume":"12","author":"Devaud","year":"2013","journal-title":"Fam Cancer."},{"key":"10.1038\/s41374-019-0298-6_bib13","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1038\/nm.3954","article-title":"High-throughput screening using patient-derived tumor xenografts to predict clinical trial drug response","volume":"21","author":"Gao","year":"2015","journal-title":"Nat Med"},{"key":"10.1038\/s41374-019-0298-6_bib14","doi-asserted-by":"crossref","unstructured":"Linnebacher M, Maletzki C, Ostwald C, Klier U, Krohn M, Klar E, et al. Cryopreservation of human colorectal carcinomas prior to xenografting. BMC Cancer. 2010;10:362.","DOI":"10.1186\/1471-2407-10-362"},{"key":"10.1038\/s41374-019-0298-6_bib15","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.1840100514","article-title":"Estimation of the fractional catabolic rate constants for the elimination of cytosolic liver enzymes from plasma","volume":"10","author":"Peltenburg","year":"1989","journal-title":"Hepatology."},{"key":"10.1038\/s41374-019-0298-6_bib16","doi-asserted-by":"crossref","first-page":"69756","DOI":"10.18632\/oncotarget.19263","article-title":"Application of in vivo imaging techniques to monitor therapeutic efficiency of PLX4720 in an experimental model of microsatellite instable colorectal cancer","volume":"8","author":"Rohde","year":"2017","journal-title":"Oncotarget."},{"key":"10.1038\/s41374-019-0298-6_bib17","first-page":"5857","article-title":"Correlation analysis of peripheral DPYD gene polymorphism with 5-fluorouracil susceptibility and side effects in colon cancer patients","volume":"7","author":"Sun","year":"2014","journal-title":"Int J Clin Exp Med."},{"issue":"11","key":"10.1038\/s41374-019-0298-6_bib18","doi-asserted-by":"crossref","first-page":"e0143194","DOI":"10.1371\/journal.pone.0143194","article-title":"Functional Characterization and Drug Response of Freshly Established Patient-Derived Tumor Models with CpG Island Methylator Phenotype","volume":"10","author":"Maletzki","year":"2015","journal-title":"PLOS ONE"},{"issue":"12","key":"10.1038\/s41374-019-0298-6_bib19","doi-asserted-by":"crossref","first-page":"e52485","DOI":"10.1371\/journal.pone.0052485","article-title":"Establishment, Characterization and Chemosensitivity of Three Mismatch Repair Deficient Cell Lines from Sporadic and Inherited Colorectal Carcinomas","volume":"7","author":"Maletzki","year":"2012","journal-title":"PLoS ONE"},{"key":"10.1038\/s41374-019-0298-6_bib20","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/s00428-016-1956-3","article-title":"Molecular pathological classification of colorectal cancer","volume":"469","author":"Muller","year":"2016","journal-title":"Virchows Arch."},{"key":"10.1038\/s41374-019-0298-6_bib21","doi-asserted-by":"crossref","DOI":"10.1038\/srep24671","article-title":"Establishment and characterization of HROC69\u2014a Crohn s related colonic carcinoma cell line and its matched patient-derived xenograft","volume":"6","author":"Kuehn","year":"2016","journal-title":"Sci Rep"},{"issue":"9","key":"10.1038\/s41374-019-0298-6_bib22","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1158\/2159-8290.CD-14-0001","article-title":"Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research","volume":"4","author":"Hidalgo","year":"2014","journal-title":"Cancer Discovery"},{"key":"10.1038\/s41374-019-0298-6_bib23","first-page":"687","article-title":"Comparison between triple therapy with octreotide, galanin and serotonin vs. irinotecan or oxaliplatin in combination with 5-fluorouracil\/leukovorin in human colon cancer","volume":"27","author":"El-Salhy","year":"2005","journal-title":"Int J Oncol"},{"key":"10.1038\/s41374-019-0298-6_bib24","doi-asserted-by":"crossref","first-page":"3285","DOI":"10.1158\/1535-7163.MCT-09-0415","article-title":"Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells","volume":"8","author":"Dorsey","year":"2009","journal-title":"Mol Cancer Ther."},{"key":"10.1038\/s41374-019-0298-6_bib25","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1111\/j.1524-4741.2009.00709.x","article-title":"Curcumin suppresses the paclitaxel-induced nuclear factor-kappaB in breast cancer cells and potentiates the growth inhibitory effect of paclitaxel in a breast cancer nude mice model","volume":"15","author":"Kang","year":"2009","journal-title":"Breast J."},{"key":"10.1038\/s41374-019-0298-6_bib26","doi-asserted-by":"crossref","first-page":"983","DOI":"10.3389\/fmicb.2018.00983","article-title":"Lactobacillus casei Variety rhamnosus probiotic preventively attenuates 5-fluorouracil\/oxaliplatin-induced intestinal injury in a syngeneic colorectal cancer model","volume":"9","author":"Chang","year":"2018","journal-title":"Front Microbiol."},{"key":"10.1038\/s41374-019-0298-6_bib27","first-page":"1531","article-title":"Molecular basis of 5-fluorouracil-related toxicity: lessons from clinical practice","volume":"34","author":"Papanastasopoulos","year":"2014","journal-title":"Anticancer Res"},{"key":"10.1038\/s41374-019-0298-6_bib28","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1002\/humu.9201","article-title":"Detailed analysis of five mutations in dihydropyrimidine dehydrogenase detected in cancer patients with 5-fluorouracil-related side effects","volume":"22","author":"Gross","year":"2003","journal-title":"Hum Mutat."},{"key":"10.1038\/s41374-019-0298-6_bib29","doi-asserted-by":"crossref","first-page":"303","DOI":"10.4149\/neo_2009_04_303","article-title":"Influence of dihydropyrimidine dehydrogenase gene (DPYD) coding sequence variants on the development of fluoropyrimidine-related toxicity in patients with high-grade toxicity and patients with excellent tolerance of fluoropyrimidine-based chemotherapy","volume":"56","author":"Kleibl","year":"2009","journal-title":"Neoplasma."},{"key":"10.1038\/s41374-019-0298-6_bib30","unstructured":"Dean L. Medical Genetics Summaries [Internet]. In: Pratt V, McLeod H, Rubinstein W, Dean L, Malheiro A, editors. Fluorouracil therapy and DPYD genotype. Bethesda, MD: National Center for Biotechnology Information; 2012. p. 2012\u20132016."},{"key":"10.1038\/s41374-019-0298-6_bib31","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1186\/s13045-018-0607-3","article-title":"Decitabine demonstrates antileukemic activity in B cell precursor acute lymphoblastic leukemia with MLL rearrangements","volume":"11","author":"Roolf","year":"2018","journal-title":"J Hematol Oncol."},{"key":"10.1038\/s41374-019-0298-6_bib32","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.3727\/096504017X14841698396900","article-title":"Simultaneous, but not consecutive, combination with folinate salts potentiates 5-fluorouracil antitumor activity in vitro and in vivo","volume":"25","author":"Di Paolo","year":"2017","journal-title":"Oncol Res."},{"key":"10.1038\/s41374-019-0298-6_bib33","doi-asserted-by":"crossref","first-page":"5880","DOI":"10.1158\/1078-0432.CCR-04-0169","article-title":"Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy","volume":"10","author":"Lecomte","year":"2004","journal-title":"Clin Cancer Res."},{"key":"10.1038\/s41374-019-0298-6_bib34","first-page":"321","article-title":"Chromosomally and microsatellite stable colorectal carcinomas without the CpG island methylator phenotype in a molecular classification","volume":"35","author":"Ostwald","year":"2009","journal-title":"Int J Oncol"}],"container-title":["Laboratory Investigation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41374-019-0298-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41374-019-0298-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722005360?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0023683722005360?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41374-019-0298-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T19:30:12Z","timestamp":1758396612000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0023683722005360"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0023683722005360"],"URL":"https:\/\/doi.org\/10.1038\/s41374-019-0298-6","relation":{},"ISSN":["0023-6837"],"issn-type":[{"value":"0023-6837","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NSG mice as hosts for oncological precision medicine","name":"articletitle","label":"Article Title"},{"value":"Laboratory Investigation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1038\/s41374-019-0298-6","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 United States & Canadian Academy of Pathology.","name":"copyright","label":"Copyright"}]}}